- Home
- PACS vs LEGN Comparison
PACS vs LEGN Comparison
Compare PACS & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PACS | LEGN |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3B | 5.9B |
| IPO Year | 2024 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PACS | LEGN |
|---|---|---|
| Price | $44.75 | $19.13 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | $45.50 | ★ $61.33 |
| AVG Volume (30 Days) | 849.9K | ★ 2.3M |
| Earning Date | 02-26-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 221.05 | N/A |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $5,288,932,000.00 | N/A |
| Revenue This Year | $10.19 | $42.68 |
| Revenue Next Year | $8.58 | $30.52 |
| P/E Ratio | $89.00 | ★ N/A |
| Revenue Growth | ★ 29.32 | N/A |
| 52 Week Low | $7.50 | $16.24 |
| 52 Week High | $48.00 | $38.42 |
Technical Indicators
Market Signals| Indicator | PACS | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Price Performance
Historical ComparisonAbout PACS PACS Group Inc.
PACS Group Inc is a post-acute healthcare company mainly focused on delivering skilled nursing care through a portfolio of independently operated facilities. The post-acute care ecosystem serves individuals who need additional help recuperating from acute conditions, illnesses, or serious medical procedures after getting discharged from the hospital. It also provides senior care, assisted living, and independent living options in some of the communities. The company has one reportable segment.
About LEGN Legend Biotech Corporation
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.